<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373150</url>
  </required_header>
  <id_info>
    <org_study_id>PXL008-011</org_study_id>
    <nct_id>NCT02373150</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of Imeglimin in Japanese Volunteers</brief_title>
  <official_title>A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Imeglimin in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of single and repeated doses of imeglimin in
      healthy Japanese subjects, and the safety and tolerability of single and repeated doses of
      imeglimin in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combined single and repeated dose groups with 3 escalating doses
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of imeglimin after single and repeated doses: - Cmax: peak plasma concentration after dosing, AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite time, - Tmax: time of peak plasma concentration of imeglimin</measure>
    <time_frame>From baseline to Day 13</time_frame>
    <description>Cmax: peak plasma concentration after dosing
AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite time
AUC0-t: area under the concentration-time curve from 0 to the time of last quantifiable concentration
Tmax: time of peak plasma concentration of imeglimin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of imeglimin: laboratory assessments</measure>
    <time_frame>From baseline to Day 13</time_frame>
    <description>routine hematology, biochemistry, coagulation and urinalysis
physical examination
12-lead ECG
vital signs
capillary glucose
incidence of adverse events</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imeglimin</intervention_name>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group A3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group A3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Japanese subjects, deemed healthy on the basis of a clinical history,
             physical examination, ECG, vital signs, and laboratory tests of blood and urine

          -  Body mass index in the range 18.0-25.0 kg/m2

          -  Willing to use reliable contraception

          -  Able to give fully informed written consent.

        Exclusion Criteria:

          -  Pregnant or lactating woman, or sexually active woman of child-bearing potential not
             using reliable contraception

          -  Clinically relevant abnormal findings at the screening assessment

          -  Clinically significant vital signs outside the acceptable range at screening

          -  Clinically relevant abnormal medical history, surgery or concurrent medical condition

          -  Acute or chronic illness

          -  Estimated glomerular filtration rate less than 80 mL/min/1.73 m2

          -  Severe adverse reaction to any drug or sensitivity to the trial medication or its
             components

          -  Significant food allergy; vegetarian or vegan

          -  Use of vitamins, herbal medicines, or over-the-counter medication (with the exception
             of paracetamol [acetaminophen]) within 7 days before first dose of trial medication,
             or prescribed medication during the 14 days before first dose of trial medication

          -  Participation in other clinical trials of unlicensed or prescription medicines, or
             loss of more than 400 mL blood, within the 3 months before first dose of trial
             medication

          -  Drug or alcohol abuse

          -  Smoking of more than 5 cigarettes daily

          -  Possibility that subject will not cooperate

          -  Positive test for hepatitis B &amp; C, HIV

          -  Objection by a General Practitioner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

